Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence

<img file="NZ526604A_D0001.tif" />

(19)

INTELLECTUAL PROPERTY OC (12) (11) Publication number: (41) Publication date: (51) Int. Cl:

Patent Application

29.04.2005

A61K31/216; A61K31/222; A61K31/485; A61K31/55;

A61P13/00;

(21) Application number:

(22) Date of filing:

(30) Priority:

NZ20010526604

28.11.2001

2000159415 DE 30.11.2000 2001EP13911 WO 28.11.2001 (71) Applicant(s): GRUENENTHAL CHEMIE (72) Inventor(s): CHRISTOPH THOMAS (54) Title:

Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence (57) Abstract:

The use of weak opioids and mixed opioid antagonists/ antagonists for the preparation of a medicament for treatment of an increased urge to urinate or urinary incontinence is disclosed. Wherein, the compounds that may be used for the preparation of the medicament include codeine or dihydrocodeine, dextropropoxyphene, meptazinol or tilidine.

This PDF First Page has been artificially created from the NZ Bibliographic Data.

The use of weak opioids and mixed opioid antagonists/antagonists for the preparation of a medicament for treatment of an increased urge to urinate or urinary incontinence is disclosed. Wherein, the compounds that may be used for the preparation of the medicament include codeine or dihydrocodeine, dextropropoxyphene, meptazinol ortilidine.

New Zealand Pafent Specification for Pafent Number 526604

526 6 04

WO 02/43713 PCT/EP01/13911

Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence

The invention relates to the use of weak opioids and mixed opioid agonists/antagonists for the preparation of a medicament for treatment of an increased urge to urinate or urinary incontinence and to corresponding medicaments and methods for treatment of an increased urge to urinate or urinary incontinence.

Urinary incontinence is the involuntary discharge of urine. This occurs in an uncontrolled manner when the pressure within the urinary bladder exceeds the pressure needed to close the ureter. Causes can be on the one hand an increased internal pressure in the bladder (e.g. due to detrusor instability) with the consequence of urgency incontinence and on the other hand a reduced sphincter pressure (e.g. following giving birth or surgical interventions) with the consequence of stress incontinence.

The detrusor is the coarsely bundled multilayered bladder wall musculature, contraction of which leads to voiding of urine, and the sphincter is the closing muscle of the urethra. Mixed forms of these types of incontinence and socalled overflow incontinence (e.g. in cases of benign prostate hyperplasia) or reflex incontinence (e.g. following damage to the spinal cord) occur. Further details in this respect are to be found in Chutka, D.S. and Takahashi, P.Y., 1998, drugs 560: 587-595.

The urge to urinate is the state, aimed at voiding of urine (miction), of increased bladder muscle tension as the bladder capacity is approached (or exceeded). This

INTELLECTUAL PROPERTY OFRCF ^n,‘ M2

3 DEC 20M

RECEIVED

WO 02/43712

PCT/EP01/13909 tensioning acts here as a stimulus to miction. An increased urge to urinate is understood here as meaning in particular the occurrence of a premature or increased and sometimes even painful urge to urinate up to so-called strangury. This consequently leads to significantly more frequent miction. Causes can be, inter alia, inflammations of the urinary bladder and neurogenic bladder disorders, and also bladder tuberculosis. However, all the causes have not yet been clarified.

An increased urge to urinate and also urinary incontinence are perceived as extremely unpleasant and there is a clear need among persons affected by these indications to achieve an improvement which is as long-term as possible.

An increased urge to urinate and in particular urinary incontinence are conventionally treated with medicaments using substances which are involved in the reflexes of the lower urinary tract (Wein, A.J., 1998, Urology 51 (suppl. 21) : 43-47) . These are usually medicaments which have an inhibiting action on the detrusor muscle, which is responsible for the internal pressure in the bladder.

These medicaments are e.g. parasympatholytics, such as oxybutynin, propiverine or tolterodine, tricyclic antidepressants, such as imipramine, or muscle relaxants, such as flavoxate. Other medicaments, which in particular increase the resistance of the urethra or of the neck of the bladder, show affinities for a-adrenoreceptors, such as ephedrine, for β-adrenoreceptors, such clenbutarol , or are hormones, such as oestradiol.

WO 02/43712

PCT/EP01/13909

Certain diarylmethylpiperazines and -piperidines are also described for this indication in WO 93/15062. For tramadol also a positive effect on bladder function has been demonstrated in a rat model of rhythmic bladder contractions (Nippon-Shinyaku, WO 98/46216). The literature furthermore contains studies on characterization of the opioid side effect of urine retention, which give some indications of the influence on bladder functions by weak opioids, such as diphenoxylate (Fowler et al., 1987 J. Urol 138:735-738) and meperidine (Doyle and Briscoe, 1976 Br J Urol 48:329-335), by mixed opioid agonists/antagonists, such as buprenorphine (Malinovsky et al., 1998 Anesth Analg 87:456-461; Drenger and Magora, 1989 Anesth Analg 69:348-353), pentazocine (Shimizu et al.

(2000) Br. J. Pharmacol. 131 (3):610-616) and nalbuphine (Malinovsky et al., 1998, loc. cit.), and by potent opioids, such as morphine (Malinovsky et al., 1998 loc. cit.; Kontani and Kawabata, (1988); Jpn J Pharmacol.

Sep;48(1):31) and fentanyl (Malinovsky et al·., 1998 loc. cit.). However, these studies were usually conducted in analgesically active concentrations.

In the case of the indications in question here, however, it should be remembered that it is in general a matter of very long-term uses of medicaments and, in contrast to many situations where analgesics are employed, those affected are faced with a situation which is very unpleasant but not intolerable. It is therefore to be ensured here - even more so than with analgesics - that side effects are avoided if the person affected does not want to exchange one evil for another. Also, analgesic actions are also

WO 02/43713

PCT/EP01/13911 largely undesirable during permanent treatment of urinary incontinence.

The object of the present invention was therefore to discover substances which are helpful for treatment of an increased urge to urinate or urinary incontinence and at the active doses preferably simultaneously show fewer side effects and/or analgesic actions, or at least to provide a useful alternative.

Surprisingly, it has now been found that certain weak opioids and mixed opioid agonists/antagonists already have an outstanding action on bladder function at low concentrations and accordingly are particularly suitable for treatment of corresponding diseases.

The invention accordingly provides the use of one of the following compounds • codeine or dihydrocodeine, • dextropropoxyphene, • meptazinol or • tilidine as the free base and/or in the form of physiologically acceptable salts for the preparation of a medicament for treatment of an increased urge to urinate or urinary incontinence.

Surprisingly, it has been found that these known compounds have a significant positive influence on physiological parameters which are of importance in cases of an increased intellectual ppqpertvHofhcf

TF N.Z

3 DEC 2004

WO 02/43712

PCT/EP01/13909 urge to urinate or urinary incontinence, which is to be seen in particular in a reduction in the interval in a model with rhythmic bladder contraction. This change can mean a significant alleviation in the symptomatic picture of patients affected.

Suitable salts in the context of this invention and in each of the uses claimed are salts of the particular active compound with inorganic or organic acids and/or a sugar substitute, such as saccharin, cyclamate of acesulfam. However, the hydrochloride is particularly preferred.

Codeine ((5a,6a)-7,8-didehydro-4,5-epoxy-3-methoxy-17methylmorphinan-6-ol) is an active compound with an antitussive, narcotic and analgesic action. It is described in the German Reichspatent (DRP) 247 180 of C.H. Boehringer of 1912.

Dihydrocodeine ((5a,6a)-4,5-epoxy-3-methoxy-17methylmorphinan-6-ol) is used as an analgesic and antitussive and is described by Stein, A.: Pharmazie (PHARAT) 10, 180 (1955).

Dextropropoxyphene ([S-(R*,S*)[-a-[2-(dimethylamino)-1methylethyl]-a-phenylbenzene-ethanol propanoate (ester)) is an analgesic described in US 2 728 779.

Meptazinol (3-(3-ethylhexahydro-l-methyl-lH-azepin-3yl)phenol), a narcotic and analgesic, is described in DE-OS

941 534 or GB 1 285 025.

WO 02/43712

PCT/EP01/13909

Tilidine (trans-2-(dimethylamino)-l-phenyl-3-cyclohexene-lcarboxylic acid ethyl ester) is described in DE 1 518 959 or US 3 557 126 and is a known analgesic and narcotic.

The use of dextropropoxyophene, codeine, meptazinol or tilidine is preferred in particular for the preparation of the medicament, preferably codeine, meptazinol or tilidine.

In a preferred embodiment according to the invention codeine is used, preferably in the form of the free base, the HBr or HI salt or as codeine phosphate.

In a preferred embodiment according to the invention tilidine is used, preferably in the form of the free base or the HCl salt, also in the form of its racemates; enantiomers, diastereomers, in particular mixtures of the enantiomers or diastereomers, or of an individual enantiomer or diastereomer.

In a preferred embodiment according to the invention meptazinol is used, preferably in the form of the free base or the HCl salt, also in the form of its racemates; enantiomers, diastereomers, in particular mixtures of the enantiomers or diastereomers, or of an individual enantiomer or diastereomer.

In a preferred embodiment according to the invention dihydrocodeine is used, preferably in the form of the free base or as dihydrocodeine tartrate.

WO 02/43712

PCT/EP01/13909

In a preferred embodiment according to the invention dextropropoxyphene is used, preferably in the form of the free base, the HCI salt or the napsylate, also in the form of its racemates; enantiomers, diastereomers, in particular mixtures of the enantiomers or diastereomers, or of an individual enantiomer or diastereomer.

Although the uses according to the invention merely display mild side effects, it may also be of advantage, for example to avoid certain forms of dependency, also to use morphine antagonists, in particular naloxone, naltrexone and/or levallorphan, in addition to these compounds. A preferred example would be tilidine and naloxone.

The invention also relates to medicaments for treatment of an increased urge to urinate or urinary incontinence which comprise as the active compound at least one of the compounds chosen from • codeine or dihydrocodeine, • dextropropoxyphene, • meptazinol or • tilidine as the free base and/or in the form of physiologically acceptable salts, and optionally additives and/or auxiliary substances.

Suitable salts in the context of this invention and in each of the uses claimed are salts of the particular active compound with inorganic or organic acids and/or a sugar

WO 02/43712

PCT/EP01/13909 substitute, such as saccharin, cyclamate or acesulfam. However, the hydrochloride is particularly preferred.

Suitable additives and/or auxiliary substances in the context of this invention are all the substances known to the expert from the prior art for achieving pharmaceutical formulations. The choice of these auxiliary substances and the amounts thereof to be employed depend on whether the medicament is to be administered orally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally or locally. Formulations in the form of tablets, chewable tablets, coated tablets, capsules, granules, drops, juices or syrups are suitable for oral administration, and solutions, suspensions, easily reconstitutable dry formulations and sprays are suitable for parenteral, topical and inhalatory administration. Suppositories for use in the rectum are a further possibility. The use in a depot in dissolved form, a carrier film or a patch, optionally with the addition of agents which promote penetration of the skin, are examples of suitable percutaneous administration forms. Examples of auxiliary substances and additives for oral administration forms are disintegrants, lubricants, binders, fillers, mould release agents, where appropriate solvents, flavouring substances, sugar, in particular carrier agents, diluents, dyestuffs, antioxidants etc. Waxes or fatty acid esters, inter alia, can be used for suppositories, and carrier substances, preservatives, suspension auxiliaries etc. can be used for compositions for parenteral administration. The amounts of active compound to be administered to patients vary according to the weight of

WO 02/43712

PCT/EP01/13909 the patient, the mode of administration and the severity of the disease. The compounds according to the invention can be released in a delayed manner from formulation forms which can be used orally, rectally or percutaneously. Appropriate sustained release formulations, in particular in the form of a once daily preparation which has to be taken only once a day, are particularly preferred for the indication according to the invention.

Medicaments which comprise at least 0.05 to 90.0% of the active compound, in particular low active dosages, in order to avoid side effects or analgesic actions, are furthermore preferred.

Preferably, in the use according to the invention of the substances for a medicament for urinary incontinence or for a medicament comprising these active compounds, a dose which is lower than that necessary for an analgesic action is employed in the medicament, that is to say dosages below the analgesic action are used. Dosages between the lower limit of the dose used for pain treatment and 10% of this dose are usual, preferably between 80% and 20% of this dose, in particular between 50 and 30%.

For the opioids, the use of which in urinary incontinence is claimed according to the invention, this means that the following concrete doses per administration are conventionally employed:

WO 02/43712

PCT/EP01/13909

<td rowspan="2"> Substance</td><td colspan="3"> Human dose [mg]</td><td colspan="3"> Dose [pg/kg]</td>

<td> usual</td><td> preferred</td><td> in part.</td><td> usual</td><td> preferred</td><td> in part.</td>

<td> Codeine</td><td> 4-40</td><td> 8-32</td><td> 12-20</td><td> 62-616</td><td> 123-493</td><td> 185-308</td>

<td> Dextropro- poxyphene</td><td> 10-100</td><td> 20-80</td><td> 30-50</td><td> 154-1540</td><td> 308-1232</td><td> 462-770</td>

<td> Meptazinol</td><td> 5-50</td><td> 10-40</td><td> 15-25</td><td> 77-770</td><td> 154-616</td><td> 231-385</td>

<td> Tilidine</td><td> 5-50</td><td> 10-40</td><td> 15-25</td><td> 77-770</td><td> 154-616</td><td> 231-385</td>

Auxiliary substances can be, for example: water, ethanol, 2-propanol, glycerol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glucose, fructose, lactose, sucrose, dextrose, molasses, starch, modified starch, gelatine, sorbitol, inositol, mannitol, microcrystalline cellulose, methylceliulose, carboxymethylcellulose, cellulose acetate, shellac, cetyl alcohol, polyvinylpyrrolidone, paraffins, waxes, naturally occurring and synthetic gums, acacia gum, alginates, dextran, saturated and unsaturated fatty acids, stearic acid, magnesium stearate, zinc stearate, glyceryl stearate, sodium lauryl sulfate, edible oils, sesame oil, coconut oil, groundnut oil, soya bean oil, lecithin, sodium lactate, polyoxyethylene and -propylene fatty acid esters, sorbitan fatty acid esters, sorbic acid, benzoic acid, citric acid, ascorbic acid, tannic acid, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, magnesium oxide, zinc oxide, silicon dioxide, titanium oxide, titanium dioxide, magnesium sulfate, zinc sulfate, calcium sulfate, potash, calcium phosphate, dicalcium phosphate, potassium bromide, potassium iodide, talc, kaolin, pectin, crospovidone, agar and bentonite.

WO 02/43712

PCT/EP01/13909

The medicaments and pharmaceutical compositions according to the invention are prepared with the aid of means, devices, methods and processes which are well-known in the prior art of pharmaceutical formulation, such as are described, for example, in Remington's Pharmaceutical Sciences, ed. A.R. Gennaro, 17th ed., Mack Publishing Company, Easton, Pa. (1985), in particular in part 8, chapter 76 to 93.

Thus e.g. for a solid formulation, such as a tablet, the active compound of the medicament, i.e. a compound of the general structure I or one of its pharmaceutically acceptable salts, can be granulated with a pharmaceutical carrier, e.g. conventional tablet constituents, such as maize starch, lactose, sucrose, sorbitol, talc, magnesium stearate, dicalcium phosphate or pharmaceutically acceptable gums, and pharmaceutical diluents, such a e.g. water, in order to form a solid composition which comprises a compound according to the invention or a pharmaceutically acceptable salt thereof in homogeneous distribution. Homogeneous distribution is understood here as meaning that the active compound is distributed uniformly over the entire composition, so that this can easily be divided into unit dose forms, such as tablets, pills or capsules, having the same action. The solid composition is then divided into unit dose forms. The tablets or pills of the medicament according to the invention or of the compositions according to the invention can also be coated or compounded in another manner in order to provide a dose form with delayed release. Suitable coating agents are, inter alia, polymeric acids and mixtures of polymeric acids

WO 02/43712

PCT/EP01/13909 with materials such as e.g. shellac, cetyl alcohol and/or cellulose acetate.

Medicaments which comprise dextropropoxyophene, codeine, meptazinol or tilidine are particularly preferred, preferably codeine, meptazinol or tilidine.

Although the medicaments according to the invention merely display mild side effects, it may be of advantage, for example to avoid certain forms of dependency, also to use morphine antagonists, in particular naloxone, naltrexone and/or levaiiorphan, in addition to the compounds according to general formula I. A preferred example would be tilidine and naloxone.

The invention also relates to a method for treatment of an increased urge to urinate or urinary incontinence in which codeine or dihydrocodeine, dextropropoxyphene, meptazinol, pethidine or tilidine in the form of their bases and/or salts of physiologically acceptable acids, optionally also in the form or their racemates; enantiomers, diastereomers, in particular mixtures of their enantiomers or diastereomers, or of an individual enantiomer or diastereomer, are used.

The following examples are intended to illustrate the invention without the subject matter of the invention being limited thereto.

WO 02/43712

PCT/EP01/13909

Examples

Example 1: Test system of cystometry on anaesthetized naive rats

The cystometric investigation of naive female rats was carried out by the method of Kimura et al. (Kimura et al., 1996, Int. J. Urol. 3:218-227). The abdomen of anaesthetized ventilated rats is opened up and the ureter is tied off. The urine is drained from the kidneys. A catheter is inserted into the bladder and fixed. Saline is infused into the bladder via this by means of an infusion pump, until the bladder shows rhythmic spontaneous activity in the form of contractions, which can be recorded via a connected pressure transducer. After stable starting values are reached, the test substance is administered i.v. in a cumulative manner. An influence on bladder function manifests itself via suppression of spontaneous contractions. The absence of contractions over a period of 10 min is the parameter for the suppression.

A suppression of spontaneous contractions in the rats was measurable with all the substances listed here, table 1 indicating the mean of the lowest dose of 3 independent experiments at which for the first time contractions are absent over a period of 10 min.

WO 02/43712

PCT/EP01/13909

<td> Compound</td><td> Lowest dose (mg/kg)</td>

<td> Tilidine</td><td> 0.5 (n=3)</td>

<td> Meptazinol</td><td> 1.0 (n=3)</td>

<td> Codeine (phosphate)</td><td> 4.7 (n=3)</td>

Table 1: (n corresponds to the number of experiments included in the value)

The substances investigated show a positive action on bladder regulation and are thus suitable for treatment of urinary incontinence.

Example 2: Parenteral administration form

38.5 g meptazinol HCI is dissolved in 1 1 of water for injection at room temperature and the solution is then adjusted to isotonic conditions by addition of anhydrous glucose for injection.

For an average patient of approx. 65 kg body weight, for example, 0.5 ml of this solution is administered, that is to say 19.25 mg or « 300 pg/kg. The dose can be administered about 3 time daily.

Example 3: Liquid oral administration form as a combination with naloxone

23.82 g tilidine HCI k H₂0 and 2.04 g naloxone HCI 2H₂O are dissolved in 874 ml purified water, 124 ml ethanol (96%) and 2 ml HCI at room temperature.

WO 02/43712

PCT/EP01/13909

For an average patient of approx. 65 kg body weight, for example, 20 drops (« 0.72 ml) of this solution are taken, that is to say 17.15 mg of active compound (corresponds to approx. 16.7 mg tilidine HCI) or 264 pg/kg. This can be taken up to 4 times daily in total.

Example 4: Solid oral sustained release administration form (sustained release capsules)

Per sustained release capsule:

<td rowspan="2"> 50 80</td><td rowspan="2"> mg mg</td><td colspan="2"> dextropropoxyphene</td>

<td> Avicel P,</td><td> H 101</td>

<td> 20</td><td> mg</td><td> lactose :</td><td> monohydrate</td>

<td> 12</td><td> mg</td><td> Eudragit</td><td> RS</td>

<td> 3</td><td> mg</td><td> Eudragit</td><td> RL</td>

<td> 3</td><td> mg</td><td> triethyl</td><td> citrate</td>

<td> 5</td><td> mg</td><td> talc</td><td></td>

173 mg total

Dextropropoxyphene HCI, microcrystalline cellulose and lactose are mixed homogeneously in a mixer and the mixture is then granulated with water. The moist granules are extruded in a screw extruder with a 0.8 mm (hole diameter) perforated plate and then rounded to pellets in a spheronizer. The pellets are dried in a drying cabinet overnight at 45°C.

The graded pellets of grain class 800 - 1,200 pm are coated with an aqueous dispersion of Eudragit RS 30D + Eudragit RL 30D, containing tiethyl citrate as a

WO 02/43712

PCT/EP01/13909 plasticizer and talc as an anti-stick agent, (solids content of the ready-to-use dispersion: 20% w/w) in a fluidized bed coater at a product temperature of approx. 30°C and then dried for 24 h at 45°C in a drying cabinet. The pellets are transferred to hard gelatine capsules of size 1 at individual doses of 173 mg.

Example of a dose: 1 capsule, that is to say for a body weight of 65 kg « 770 pg/kg. 2 capsules a day are usually taken.

Example 5: Solid oral sustained release administration form (sustained release tablets)

Per sustained release tablet:

<td> 17</td><td> mg</td><td> codeine phosphate H₂O</td>

<td> 143</td><td> mg</td><td> microcrystalline cellulose</td>

<td> 94</td><td> mg</td><td> methylhydroxypropylcellulose</td>

<td></td><td></td><td> 100,000 mPa·s</td>

<td> 3</td><td> mg</td><td> highly disperse silicon dioxide</td>

<td> 3</td><td> mg</td><td> magnesium stearate</td>

<td> 260</td><td> mg</td><td> total</td>

The auxiliary substances and the active compound are mixed homogeneously in a mixer and the mixture is then pressed on a tablet press to give tablets with a 0 of 9 mm.

WO 02/43712

PCT/EP01/13909

Example of a dose: 1 tablet, that is to say for a body weight of 65 kg « 262 pg/kg. 2 tablets a day are usually taken.

<img file="NZ526604A_D0002.tif" />

WO 02/43712

PCT/EP01/13909